Skyrizi

Skyrizi is a biologic that was approved for the treatment of moderate-to-severe plaque psoriasis in 2019. It was also approved as a treatment for psoriatic arthritis in 2022.

What is Skyrizi?

Skyrizi (also known by its generic name risankizumab-rzaa) was approved by the FDA in April 2019 for the treatment of moderate-to-severe plaque psoriasis in adults. Skyrizi was approved by the FDA in January 2022 for the treatment of active psoriatic arthritis (PsA) in adults.

For both plaque psoriasis and PsA, Skyrizi is given by injection under the skin at week 0 (the first week of treatment) and week 4, and then every 12 weeks afterwards.

To learn more, please visit the Skyrizi website.

A shot of a woman's legs as she is walking on a path through the woods.

Second SKYRIZI® Indication Approved

FDA approves SKYRIZI® for adults with active PsA

Find out more

Two women wearing sunglasses and smiling outside.

New Dosing Available for SKYRIZI®

SKYRIZI® (risankizumab-rzaa) is now available in the U.S. as a single dose injection for the treatment of adults with moderate-to-severe plaque psoriasis.

Read article

Illustrated graphic of people around a rocket ship and computer.

Advance Weekly

Get the latest news on new treatment options from NPF.

Stay up to date

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today